Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAF vs TDF in HBeAg-negative chronic hepatitis B
CTR20150267Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tenofovir alafenamide in hepatitis B (HBV), sponsored by Gilead Sciences. Started Aug 2015; status: completed.
02
Drugs
tenofovir alafenamide
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on CTR20150267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20150267.